Information about Elotuzumab
Liver safety of Elotuzumab
Elotuzumab has been implicated in rare instances of transient, marked serum enzyme elevations, but has not been linked to instances of clinically apparent liver injury with jaundice.
Mechanism of action of Elotuzumab
Elotuzumab (el" oh tooz' ue mab) is humanized IgG1 monoclonal antibody to the cell surface receptor signaling lymphocyte activation molecule family member 7 (SLAMF7), which is a transmembrane glycoprotein that is frequently overexpressed on multiple myeloma cells and is found normally on natural killer (NK) cells. The monoclonal antibody binds to the cell surface receptor and triggers cell apoptosis of cancer cells and activation of NK cells which may increase its antineoplastic activity. In preregistration trials, the addition of elotuzumab to lenalidomide and dexamethasone led to an increase in overall response rates and prolongation of progression-free survival.
FDA approval information for Elotuzumab
Elotuzumab was given accelerated approval for use in the United States in 2015. Current indications are as therapy of refractory multiple myeloma administered in combination with lenalidomide (or bortezomib) and dexamethasone or as monotherapy in patients who have failed at least three previous regimens. Elotuzumab is available as a powder for reconstitution in single use vials of 300 or 400 mg under the brand name Empliciti.
Dosage and administration for Elotuzumab
The recommended dose is 10 mg/kg intravenously every week for 2 cycles and every 2 weeks thereafter until disease progression or unacceptable toxicities occur.
Side effects of Elotuzumab
Premedication with dexamethasone, diphenhydramine, ranitidine and acetaminophen is recommended. side effects are common and can include infusion reactions, fatigue, diarrhea, constipation, anorexia, fever, cough, nasopharyngitis, peripheral neuropathy and pneumonia. Uncommon, but potentially severe adverse reactions include severe infusion reactions, bacterial infections and secondary malignancies.